

Suzette Delalogue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8189667/publications.pdf>

Version: 2024-02-01

110
papers

16,283
citations

36303

51
h-index

27406

106
g-index

116
all docs

116
docs citations

116
times ranked

20737
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	2.8	49
2	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	1.6	23
3	MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40â€“70: Focus on recruitment strategy in France. <i>La Presse MÃ©dicale Open</i> , 2022, 3, 100022.	0.4	4
4	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821.	1.9	23
5	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162.	1.6	18
6	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 166, 300-308.	2.8	11
7	Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. <i>Analytical Chemistry</i> , 2022, 94, 6297-6303.	6.5	13
8	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38
9	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	1.6	23
10	Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the â€œMy Personal Breast Screeningâ€“(MyPeBS) randomised clinical trial. <i>BMC Cancer</i> , 2022, 22, 507.	2.6	32
11	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	1.6	11
12	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	9.4	28
13	Impact of body mass index on overall survival in patients with metastatic breast cancer. <i>Breast</i> , 2021, 55, 16-24.	2.2	17
14	Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. <i>Breast Cancer Research</i> , 2021, 23, 9.	5.0	4
15	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. <i>Oncolmmunology</i> , 2021, 10, 1859064.	4.6	6
16	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.7	179
17	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , 2021, 7, 41.	5.2	33
18	Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 501-509.	2.5	18

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327.	2.8	55
20	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	11.2	72
21	BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial. <i>Quality of Life Research</i> , 2021, , 1.	3.1	2
22	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	2.8	18
23	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021, 153, 123-132.	2.8	25
24	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
25	Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project. <i>PLoS ONE</i> , 2021, 16, e0255017.	2.5	1
26	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	6.4	37
27	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	1.2	354
28	Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. <i>Breast</i> , 2021, 60, 138-146.	2.2	5
29	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	27.0	363
30	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020, 38, 734-743.	1.6	69
31	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	10.7	161
32	Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBC) Tj ETQq0 0 0. BT /Overlock 10 T		
33	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	12.8	71
34	Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016. <i>European Journal of Cancer</i> , 2020, 137, 240-249.	2.8	2
35	A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016". <i>European Journal of Cancer</i> , 2020, 140, 165-166.	2.8	4
36	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772.	1.6	80

#	ARTICLE	IF	CITATIONS
37	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	27.6	178
38	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.9	4
39	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. <i>European Journal of Cancer</i> , 2020, 129, 60-70.	2.8	103
40	The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 703-716.	4.2	28
41	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1087-1087.	1.6	2
42	Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2000-2000.	1.6	17
43	MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 506-506.	1.6	44
44	Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1107-TPS1107.	1.6	0
45	UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup. <i>European Journal of Cancer</i> , 2019, 122, 91-100.	2.8	8
46	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
47	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
48	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370.	10.7	59
49	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	2.8	25
50	Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual & volumetric analysis. <i>British Journal of Radiology</i> , 2018, 91, 20170163.	2.2	3
51	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
52	Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety. <i>Breast Journal</i> , 2018, 24, 154-160.	1.0	17
53	Value of whole breast magnetic resonance elastography added to MRI for lesion characterization. <i>NMR in Biomedicine</i> , 2018, 31, e3795.	2.8	25
54	Patient-assisted compression helps for image quality reduction dose and improves patient experience in mammography. <i>European Journal of Cancer</i> , 2018, 103, 137-142.	2.8	21

#	ARTICLE	IF	CITATIONS
55	All simulation models of breast cancer are wrong but some are useful. <i>The Lancet Global Health</i> , 2018, 6, e818-e819.	6.3	0
56	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer—patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. <i>European Journal of Cancer</i> , 2017, 75, 323-332.	2.8	22
57	Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?. <i>European Journal of Cancer</i> , 2017, 77, 153-154.	2.8	0
58	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	27.0	2,256
59	Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?. <i>European Journal of Cancer</i> , 2017, 85, 23-30.	2.8	3
60	Targeting PI3K/AKT pathway in triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1293-1294.	10.7	39
61	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
62	Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the <i>E3N-EPIC</i> cohort. <i>International Journal of Cancer</i> , 2016, 138, 2415-2427.	5.1	37
63	Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality. <i>BMJ</i> , The, 2016, 355, i6745.	6.0	2
64	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137.	2.8	33
65	Added Value of Contrast-Enhanced Spectral Mammography in Postscreening Assessment. <i>Breast Journal</i> , 2016, 22, 520-528.	1.0	38
66	Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience. <i>Breast Journal</i> , 2016, 22, 83-89.	1.0	23
67	Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. <i>Breast Journal</i> , 2016, 22, 96-100.	1.0	0
68	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	27.0	1,427
69	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	9.1	90
70	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	10.7	444
71	Ki67—no evidence for its use in node-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 296-301.	27.6	58
72	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	12.6	367

#	ARTICLE	IF	CITATIONS
73	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	9.1	91
74	Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions. <i>European Journal of Radiology</i> , 2014, 83, 773-777.	2.6	103
75	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	2.2	135
76	Cancer cell's autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	30.7	823
77	Exploring frontiers: Use of complementary and alternative medicine among patients with early-stage breast cancer. <i>Breast</i> , 2014, 23, 279-285.	2.2	59
78	Chk1 as a new therapeutic target in triple-negative breast cancer. <i>Breast</i> , 2014, 23, 250-258.	2.2	50
79	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1082-1082.	1.6	0
80	Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11528-e11528.	1.6	0
81	Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11087-11087.	1.6	1
82	CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. <i>Journal of Medical Genetics</i> , 2013, 50, 486-489.	3.2	131
83	The role of Oncoplastic Breast Surgery in the management of breast cancer treated with primary chemotherapy. <i>Breast</i> , 2013, 22, 1189-1193.	2.2	60
84	Outcome in breast molecular subtypes according to nodal status and surgical procedures. <i>American Journal of Surgery</i> , 2013, 205, 662-667.	1.8	43
85	Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. <i>Cancer Research</i> , 2013, 73, 2247-2258.	0.9	86
86	Triple-negative breast cancer: are we making headway at least?. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 195-210.	3.2	75
87	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929.	1.6	244
88	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012, 30, 1193-1202.	2.6	71
89	Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer. <i>Journal of the American College of Cardiology</i> , 2011, 57, 445-452.	2.8	191
90	Laser thermal therapy: Real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. <i>Lasers in Surgery and Medicine</i> , 2011, 43, 943-950.	2.1	184

#	ARTICLE	IF	CITATIONS
91	Dual-energy contrast-enhanced digital mammography: initial clinical results. <i>European Radiology</i> , 2011, 21, 565-574.	4.5	233
92	Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1236-1238.	1.6	65
93	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 341-345.	1.3	39
94	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 429-437.	2.5	99
95	Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. <i>Radiotherapy and Oncology</i> , 2010, 96, 199-203.	0.6	59
96	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. <i>Oncologist</i> , 2009, 14, 1182-1188.	3.7	59
97	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. <i>Clinical Cancer Research</i> , 2009, 15, 441-451.	7.0	300
98	New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. <i>European Journal of Radiology</i> , 2009, 69, 14-23.	2.6	82
99	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 381-390.	10.7	55
100	Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2008, 14, 7004-7010.	7.0	350
101	Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 292-300.	1.6	140
102	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	30.7	2,657
103	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	6.0	491
104	Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. <i>Anticancer Research</i> , 2007, 27, 547-55.	1.1	51
105	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. <i>Cancer</i> , 2006, 107, 1459-1466.	4.1	55
106	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8331-8339.	1.6	266
107	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. <i>Journal of Clinical Oncology</i> , 2004, 22, 3302-3308.	1.6	389
108	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. <i>Cancer</i> , 2004, 101, 918-925.	4.1	62

#	ARTICLE	IF	CITATIONS
109	Gemcitabine in Patients With Solid Tumors and Renal Impairment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 289-293.	1.3	23
110	An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. American Journal of Surgery, 2003, 185, 158-164.	1.8	175